E.g., 07/25/2016
E.g., 07/25/2016
July 14, 2016

ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) announced today the 14 practices participating in the 2016 Quality Training Program. The program is designed to train oncology health care providers to investigate and implement data-driven quality improvement and manage clinical and administrative processes and outcomes.

June 29, 2016

ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) announced today the appointment of James M. Ford, MD, as Editor-in-Chief of the Society’s new journal, JCO Precision Oncology (JCO PO).

June 29, 2016

“ASCO commends Food and Drug Administration (FDA) Commissioner Dr. Robert Califf for his selection of Dr. Richard Pazdur to lead the agency’s new Oncology Center of Excellence. In his nearly 20 years with the FDA, Dr. Pazdur has worked innovatively to dramatically reduce the amount of time to review new products and increase the number of safe and effective oncology products available to cancer patients. He consistently demonstrates the necessary leadership and commitment to improving cancer care for directing this new center to carry out its mission."

June 28, 2016

Alexandria, VA - The American Society of Clinical Oncology (ASCO) voiced its strong opposition to the proposed Medicare Part B demonstration project in comments submitted for today’s  U.S. Senate Finance Committee hearing, "Examining the Proposed Medicare Part B Drug Demonstration." ASCO underscored the urgent need to advance a fairer and more responsible payment system for oncology than what is offered in the ill-advised proposal from the Centers for Medicare & Medicaid Services (CMS)—calling on CMS to withdraw the proposal or urging Congress to intervene before this flawed experiment irreparably harms the cancer care delivery system.

June 28, 2016

Alexandria, VA —The American Society of Clinical Oncology (ASCO) submitted comments on the Centers for Medicare & Medicaid Services (CMS) proposed rule published in the Federal Register on May 9, 2016 to implement the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). In its comments, ASCO urges CMS to allow stakeholders enough time to prepare and report correctly in January 2017.  

June 27, 2016

ALEXANDRIA, Va.— The American Society of Clinical Oncology (ASCO) and CancerLinQ LLC will join Vice President Joe Biden and other leaders in the cancer community for the Cancer Moonshot Summit at Howard University, on June 29, to launch new collaborations and exchange ideas on solving the complexities of cancer care.

June 6, 2016

CHICAGO - A pilot study revealed large differences in median retail prices for 23 cancer drugs in seven different countries, with the highest retail prices identified in the United States and the lowest in India and South Africa. Notably, after monthly drug price is expressed as a percentage of domestic product per capita at purchasing power parity (GDPcapPPP), cancer drugs appear to be less affordable in low-income countries, despite the lower retail prices. The study will be featured in a press briefing today and presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 6, 2016

CHICAGO - For breast cancer survivors who carry mutations in BRCA genes, preventive surgery can substantially reduce the risk of future breast and ovarian cancer. However, it appears that black women are far less likely to receive these widely recommended procedures than white or Hispanic women, according to a populationbased study of breast cancer survivors in Florida.

June 6, 2016

CHICAGO – An analysis of health claims data from 2007-2014 on more than 28,000 patients found that a large proportion of patients with advanced solid tumors received at least one form of aggressive care within the last 30 days of life.

June 6, 2016

CHICAGO – A Web-mediated follow-up application (Moovcare™) improves advanced lung cancer survival, according to a French multicenter randomized phase III study. Researchers analyzed the association and evolution of self-reported clinical symptoms over time. The median overall survival of patients who used the application was 19 months, compared to 12 months for those who received standard follow-up care. Patient quality of life was also better among patients who used the application. The study will be featured in a press briefing today and presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 6, 2016

ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) announced today that Bayer and Merck are the most recent companies to sign on to provide study drugs at no cost to patients enrolled in the Targeted Agent and Profiling Utilization Registry (TAPUR) study, joining six other companies in ASCO’s first-ever clinical trial. Since opening on March 14, 2016, 18 participants have enrolled and are receiving study treatment, and 31 more have provided consent and are in, or have completed, the screening process. These numbers continue to grow daily.

June 6, 2016

CHICAGO - Vice President Joseph Biden addressed the nation's oncology professionals today at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The Vice President thanked oncologists for their commitment to patient care and their contributions to the nation's growing understanding of cancer, and called on them to provide bold new ideas that can advance the National Cancer Moonshot Initiative. With more than 35,000 attendees, ASCO's Annual Meeting is the world's largest gathering of cancer doctors focused on groundbreaking clinical research advances and the most promising treatments in patient care. 

June 5, 2016

CHICAGO – A Canadian-led randomized phase III trial found that adding temozolomide (Temodar) chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide, significantly improved survival of elderly patients with glioblastoma, reducing the risk of death by 33%.

June 5, 2016

CHICAGO – Historically, less than 50% of children with high-risk neuroblastoma live five or more years after diagnosis. A National Cancer Institute (NCI) funded phase III trial performed by the Children’s Oncology Group found that adding a second autologous stem-cell transplant (ASCT, a transplant that uses the patient’s own stem cells) to standard therapy improves outcomes for these patients.

June 5, 2016

CHICAGO – Initial findings from a pivotal phase III trial showed that daratumumab (DARZALEX) added to a standard two-drug regimen (bortezomib and dexamethasone) markedly improved outcomes for patients with recurrent or refractory multiple myeloma.

Pages